Australia's HealthLinx Collaborates with Bruker Daltonics on Mass Spectrometry-Based Disease-Specifi
At the Biomarker World Conference 2005 in Philadelphia, HealthLinx Pty. Limited, based in Melbourne, Australia, yesterday announced that it has entered into a collaboration with Bruker Daltonics Inc., a developer and provider of innovative life science tools based on mass spectrometry. The collaboration focuses on technology transfer and cooperation between the two firms to develop disease-specific assays for use in in-vitro diagnostic (IVD) research and clinical trials using Bruker Daltonics' ClinProt platform technology for clinical proteomics.
The collaboration involves the on-going discovery of new biomarkers for predictive diagnostic applications using Bruker Daltonics' autoflex MALDI-TOF mass spectrometer in combination with proprietary ClinProt magnetic bead sample preparation, and ClinProTools software for advanced visualisation and bioinformatics. HealthLinx will apply this technology platform to develop and commercialise biomarker applications in women's health for both research and clinical diagnostics.